Drugs / VXCO-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05938075 | Aug 2023 → Jul 2024 | COVID-19 | Vaccine Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05870839 | May 2023 → Apr 2024 | COVID-19 | Vaccine Company, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXCO-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05870839 ↗ |
| Modality | Vaccine | “Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States” NCT05870839 ↗ |
| Route | Intramuscular | “via intramuscular (IM) injection” NCT05870839 ↗ |